Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center

In 2012, the Barcelona Clinic Liver Cancer (BCLC) system designated a single large hepatocellular carcinoma (SLHCC) (>5 cm) as BCLC stage A rather than stage B. However, a recent study from western countries reported that prognosis following liver resection (LR) among patients with SLHCC was simi...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020-03, Vol.15 (3), p.e0230897-e0230897
Main Authors: Liu, Yueh-Wei, Lin, Chih-Che, Yong, Chee-Chien, Wang, Chih-Chi, Chen, Chao-Long, Wang, Jing-Houng, Yen, Yi-Hao
Format: Article
Language:English
Subjects:
Age
Alcohol use
Biology and Life Sciences
Cancer
Carcinoma
Confidence intervals
Hepatitis
Hepatocellular carcinoma
Hospitals
Internal medicine
Liver
Liver cancer
Liver diseases
Medical prognosis
Medicine
Medicine and Health Sciences
Mortality
Patients
Prognosis
Surgery
Surgical clinics
Survival analysis
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 2012, the Barcelona Clinic Liver Cancer (BCLC) system designated a single large hepatocellular carcinoma (SLHCC) (>5 cm) as BCLC stage A rather than stage B. However, a recent study from western countries reported that prognosis following liver resection (LR) among patients with SLHCC was similar to that among patients with BCLC stage B. We aim to evaluate the prognosis following LR among patients with SLHCC from an Asian high-volume liver surgery center. Patients who underwent curative-intent LR for histologically proven HCC between 2011 and 2017 were enrolled using an HCC registry database. Overall survival (OS) among patients with BCLC stages 0, A, and B was examined. Patients with a SLHCC were classified as BCLC stage A1. Among 543 patients, 89 (16.4%) were BCLC stage 0, 289 (53.2%) were BCLC stage A, 92 (16.9%) were BCLC stage A1, and 73 (13.4%) were BCLC stage B. The median follow-up was 38 months. The five-year OS rates among patients with BCLC stages 0, A, A1, and B were 83.5%, 83.7%, 77.4%, and 55.4%, respectively (p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0230897